
CLAIMS

1. A compound of formula (I)



(I)

wherein

Y^1 and Y^2 are independently CH_2 or O;

R^1 is OH and R^2 is NH_2 or R^1 is NH_2 and R^2 is H;

R^3 is OH and R^4 is NH_2 or R^3 is NH_2 and R^4 is H;

R^5 = OH, F;

R^6 = OH, F;

provided Y^1 and Y^2 are not both O;

or a pharmaceutically acceptable salt thereof.

2. A compound or pharmaceutically acceptable salt thereof according to claim 1 wherein Y^1 is CH_2 and Y^2 is O.

3. A compound or pharmaceutically acceptable salt thereof according to claim 1 wherein Y^1 is O and Y^2 is CH_2.

4. A compound or pharmaceutically acceptable salt thereof according to claim 1 wherein Y^1 and Y^2 are both CH_2.

5. A compound or pharmaceutically acceptable salt thereof according to claims 1-4 wherein R^3 is NH_2 and R^4 is H.

6. A compound or pharmaceutically acceptable salt thereof according to claims 1-4 wherein R^2 is NH_2 and R^1 is OH.

7. A compound or pharmaceutically acceptable salt thereof according to claims 1-6 wherein R^3 is NH_2, R^4 is H, R^2 is NH_2 and R^1 is OH.

8. A compound or pharmaceutically acceptable salt thereof according to claims 1-7 wherein R^3 is NH_2, R^4 is H, R^2 is NH_2, R^1 is OH, R^5 is OH and R^6 is OH.

9. A compound or pharmaceutically acceptable salt thereof according to claim 1 which is

(1*S*,6*R*,8*R*,9*S*,10*R*,15*R*,17*R*,18*R*)-17-(2-Amino-6-oxo-6,9-dihydro-1*H*-purin-9-yl)-8-(6-amino-9*H*-purin-9-yl)-3,9,12,18-tetrahydroxy-2,4,11,13-tetraoxa-3λ^5,12λ^5-diphosphatricyclo[13.2.1.0^{6,10}]octadecane-3,12-dione;

(1*R*,6*R*,8*R*,9*S*,10*R*,15*R*,17*R*,18*R*)-17-(2-Amino-6-oxo-6,9-dihydro-1*H*-purin-9-yl)-8-(6-amino-9*H*-purin-9-yl)-3,9,12,18-tetrahydroxy-2,4,11,13,16-pentaoxa-3λ^5,12λ^5-diphosphatricyclo[13.2.1.0^{6,10}]octadecane-3,12-dione;

(1*S*,6*R*,8*R*,9*R*,10*S*,15*R*,17*R*,18*R*)-17-(2-Amino-6-oxo-6,9-dihydro-1*H*-purin-9-yl)-8-(6-amino-9*H*-purin-9-yl)-3,9,12,18-tetrahydroxy-2,4,7,11,13-pentaoxa-3λ^5,12λ^5-diphosphatricyclo[13.2.1.0^{6,10}]octadecane-3,12-dione; or

(1*S*,6*R*,8*R*,9*R*,10*R*,15*R*,17*R*,18*R*)-17-(2-Amino-6-oxo-6,9-dihydro-1*H*-purin-9-yl)-8-(6-amino-9*H*-purin-9-yl)-9-fluoro-3,12,18-trihydroxy-2,4,7,11,13- pentaoxa-3λ^5,12λ^5-diphosphatricyclo[13.2.1.0^{6,10}]octadecane-3,12-dione.

10. A pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to claims 1-9 and one or more of pharmaceutically acceptable excipients.

11. A combination comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof according to claims 1-9 and at least one further therapeutic agent.